Blockchain Registration Transaction Record

NRx Pharmaceuticals Seeks FDA Approval for Preservative-Free Ketamine Amid Shortage

NRx Pharmaceuticals files for FDA approval of NRX-100, a preservative-free ketamine, addressing U.S. shortage and enhancing drug safety. Learn more about this breakthrough.

This news is crucial as it highlights a potential solution to the severe ketamine shortage in the U.S., affecting anesthesia and pain management treatments. NRx Pharmaceuticals' preservative-free formulation could improve patient safety by eliminating toxic preservatives, aligning with health initiatives. The company's efforts may expedite access to essential medications, benefiting healthcare providers and patients alike.